arrow_back Civic Audit
Share share

Request for Information on COVID-19 Vaccine IP Waiver

This document is a request to the U.S. President to provide information to the House of Representatives regarding a proposed waiver of intellectual property rights for COVID-19 vaccines. The aim is to assess whether such a waiver would truly increase vaccine supply and accelerate the pandemic's end, and if China would gain access to these technologies.
Key points
The House wants to know if waiving intellectual property rights for COVID-19 vaccines will increase global supply and delivery.
The request also seeks to determine if such a waiver will accelerate the end of the COVID-19 pandemic.
There is concern about whether China would gain access to vaccine patents, even if explicitly excluded from the waiver.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 117_HRES_1169
Sponsor: Rep. Smith, Adrian [R-NE-3]
Process start date: 2022-06-09
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Requesting the President to transmit certain information to the House of Representatives relating to the proposed waiver of intellectual property commitments under the World Trade Organization Agreement on Trade- Related Aspects of Intellectual Property Rights.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HRES_1169.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-06-09.

What are the main provisions?

Key points include:

  • The House wants to know if waiving intellectual property rights for COVID-19 vaccines will increase global supply and delivery.
  • The request also seeks to determine if such a waiver will accelerate the end of the COVID-19 pandemic.
  • There is concern about whether China would gain access to vaccine patents, even if explicitly excluded from the waiver.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Smith, Adrian [R-NE-3].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Trade.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

What is the impact of this bill?

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Health Courts and Law Economy